CME webinar: Intimate Partner Violence: Driving Forward Toward Solutions (recorded)
Sep. 2023Important Notices
Marlex Pharmaceuticals Inc. is recalling two lots of this drug because of a label mix-up. Bottles of Digoxin Tablets USP 0.125 mg are incorrectly labeled and contain Digoxin Tablets USP 0.25 mg. Bottles of Digoxin Tablets USP 0.25 mg are incorrectly labeled and contain Digoxin Tablets USP 0.125 mg. This drug is used for the treatment of mild to moderate heart failure. Read the full text of the voluntary Digoxin recall.
Recent Announcements
CME Webinar: The State of Telehealth in 2026
Please join us for a live, CME-accredited webinar on Tuesday, Jan. 27, from noon to 1 p.m. that will share updates on the state of telehealth for 2026.Dec. 2025Education/Webinars
Formulary updates effective Jan. 1, 2026
Review upcoming policy and operational updatesDec. 2025Pharmacy Updates
Voluntary nationwide recall: Famotidine (Fresenius – November)
Fresenius Kabi USA, LLC is recalling three lots (6133156, 6133194, and 6133388) of Famotidine Injection, USP, 20 mg per 2 mL. Famotidine is used to treat excessive secretion of stomach acid or stomach ulcers.Nov. 2025Pharmacy Updates